# Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo

> **NCT01064024** · PHASE3 · COMPLETED · sponsor: **Amneal Pharmaceuticals, LLC** · enrollment: 233 (actual)

## Conditions studied

- Pain
- Urinary Tract Infections

## Interventions

- **DRUG:** Phenazopyridine Hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01064024
- **Lead sponsor:** Amneal Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2013-01-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01064024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01064024, "Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01064024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*